
- ONCOLOGY Vol 16 No 8
- Volume 16
- Issue 8
Clinton/Reid Bill Would Boost Cancer Tracking at CDC
Now that President Bush has appointed Julie Gerberding to head the Centers for Disease Control and Prevention (CDC), groups like the Trust for America’s Health are urging her to make cancer tracking a priority.
Now that President Bush has appointed Julie Gerberding to head the Centersfor Disease Control and Prevention (CDC), groups like the Trust for America’sHealth are urging her to make cancer tracking a priority.
A new billthe Nationwide Health Tracking Actintroduced by Sen. HillaryClinton (D-NY) and Sen. Harry Reid (D-Nev) would authorize $227.5 million a yearfor expansion of a pilot CDC chronic disease tracking program. The Clinton/Reidbill, which has a counterpart in the House, grew out of hearings held in Fallon,Nev, and Long Island, NY, that focused on possible environmental links to cancerin those communities.
Congress gave the CDC $17.5 million in fiscal 2002 to help get itsenvironmental health-tracking program off the ground. But at that funding level,the program’s reach is limited. Shelley Hearne, executive director of theTrust, points out that Congress just gave the CDC an extra $1 billion forbioterrorism. "But this funding and the CDC’s guidelines on how to spendit do not help the nation prepare for the number 1 killer of Americans todaychronicdiseases like cancer, asthma, and Parkinson’s disease," she states.
Articles in this issue
almost 24 years ago
Irinotecan and Other Agents in New Combinations and Other Tumor Typesalmost 24 years ago
New Edition of Cancer Care’s Helping Hand Availablealmost 24 years ago
Handbook of Gynecologic Oncologyalmost 24 years ago
House Restores Some Medicare Physician Pay Cutsalmost 24 years ago
Medicare Proposes Calendar 2003 Pay Ratealmost 24 years ago
Mathematical Modeling for Breast Cancer Risk AssessmentNewsletter
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Related Content


130 Sacituzumab Govitecan (SG) + Pembrolizumab (Pembro) Vs Chemotherapy (Chemo) + Pembro in Previously Untreated PD-L1–Positive Advanced Triple-Negative Breast Cancer (TNBC): Primary Results From the Randomized Phase 3 ASCENT-04/KEYNOTE-D19 Study
















































